These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22717454)

  • 1. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis.
    Rutgeerts PJ; Fedorak RN; Hommes DW; Sturm A; Baumgart DC; Bressler B; Schreiber S; Mansfield JC; Williams M; Tang M; Visich J; Wei X; Keir M; Luca D; Danilenko D; Egen J; O'Byrne S
    Gut; 2013 Aug; 62(8):1122-30. PubMed ID: 22717454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis.
    Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT
    J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.
    Vermeire S; O'Byrne S; Keir M; Williams M; Lu TT; Mansfield JC; Lamb CA; Feagan BG; Panes J; Salas A; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Tew GW; Luca D; Tang MT; Diehl L; Eastham-Anderson J; De Hertogh G; Perrier C; Egen JG; Kirby JA; van Assche G; Rutgeerts P
    Lancet; 2014 Jul; 384(9940):309-18. PubMed ID: 24814090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
    Tang MT; Keir ME; Erickson R; Stefanich EG; Fuh FK; Ramirez-Montagut T; McBride JM; Danilenko DM
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1440-1452. PubMed ID: 29601644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
    Tew GW; Hackney JA; Gibbons D; Lamb CA; Luca D; Egen JG; Diehl L; Eastham Anderson J; Vermeire S; Mansfield JC; Feagan BG; Panes J; Baumgart DC; Schreiber S; Dotan I; Sandborn WJ; Kirby JA; Irving PM; De Hertogh G; Van Assche GA; Rutgeerts P; O'Byrne S; Hayday A; Keir ME
    Gastroenterology; 2016 Feb; 150(2):477-87.e9. PubMed ID: 26522261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.
    Sandborn WJ; Vermeire S; Tyrrell H; Hassanali A; Lacey S; Tole S; Tatro AR;
    Adv Ther; 2020 Jul; 37(7):3417-3431. PubMed ID: 32445184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison.
    Motaghi E; Ghasemi-Pirbaluti M; Zabihi M
    Pharmacol Res; 2019 Jan; 139():120-125. PubMed ID: 30395950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
    Zhang W; Scalori A; Fuh F; McBride J; She G; Kierkus J; Korczowksi B; Li R; Abouhossein M; Kadva A; Park KT; Tang MT
    Inflamm Bowel Dis; 2022 Sep; 28(9):1348-1356. PubMed ID: 34849918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.
    Danese S; Rudziński J; Brandt W; Dupas JL; Peyrin-Biroulet L; Bouhnik Y; Kleczkowski D; Uebel P; Lukas M; Knutsson M; Erlandsson F; Hansen MB; Keshav S
    Gut; 2015 Feb; 64(2):243-9. PubMed ID: 25304132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
    Sandborn WJ; Colombel JF; Frankel M; Hommes D; Lowder JN; Mayer L; Plevy S; Stokkers P; Travis S; Van Assche G; Baumgart DC; Targan SR
    Gut; 2010 Nov; 59(11):1485-92. PubMed ID: 20947884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
    D'Amico F; Danese S; Peyrin-Biroulet L
    Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.
    Sandborn WJ; Cyrille M; Hansen MB; Feagan BG; Loftus EV; Rogler G; Vermeire S; Cruz ML; Yang J; Boedigheimer MJ; Abuqayyas L; Evangelista CM; Sullivan BA; Reinisch W
    Gastroenterology; 2019 Mar; 156(4):946-957.e18. PubMed ID: 30472236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.